FPL 66564
FPL 66564 is a short-acting angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 5.7 nM against rabbit ACE. FPL 66564 inhibits ACE activity at the functional level and is hydrolyzed in human blood into inactive hydrophilic metabolites. FPL 66564 modulates angiotensin I-induced pressor responses in anesthetized rats, and its effects rapidly return to baseline after cessation of intravenous infusion. FPL 66564 can be used for research on cardiovascular regulation related to critical illness.
For research use only. We do not sell to patients.
- CAS No.: 140369-78-4
- Formula: C8H14O4S2
- Molecular Weight:238.32
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
ACE 5.7 nM (IC50) |
In Vitro
FPL 66564 is degraded in human blood with a half-life of 14 minutes to form inactive, small hydrophilic products[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rat (anesthetized with urethane)[2]
-
Dosage:100 nmol/kg/min; 300 nmol/kg/min; 1000 nmol/kg/min
-
Administration:i.v.; continuous infusion
-
Result:Achieved rapid equilibrium of pressor response inhibition, followed by a sustained plateau.
Maintained ~90-95% inhibition of pressor response during infusion at 1000 nmol/kg/min dose.
Maintained ~75-80% inhibition during infusion at 300 nmol/kg/min dose.
Maintained ~60-65% inhibition during infusion at 100 nmol/kg/min dose.
Rapidly dissipated inhibitory effect on cessation of infusion, with all groups returning to near-baseline levels of inhibition (≤25%) by 60 minutes post-infusion.
Chemical Information
-
CAS No. 140369-78-4
-
Molecular Weight 238.32
-
Formula C8H14O4S2
-
SMILES
SC[C@@H](C)C(O[C@H](C(O)=O)CSC)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)